Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
LRRC32 Biologics Sequence Review Report 2026: Transforming growth factor beta activator LRRC32 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRRC32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP15 Biologics Sequence Review Report 2026: Matrix metalloproteinase-15 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP15 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRP12 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 12 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRP12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR156 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 156 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR156 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPRASP2 Biologics Sequence Review Report 2026: G protein-coupled receptor-associated sorting protein 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPRASP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRP10 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 10 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of LRP10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ILF3 Biologics Sequence Review Report 2026: Interleukin enhancer-binding factor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ILF3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CXCL8 Biologics Sequence Review Report 2026: Interleukin-8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CXCL8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR149 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 149 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR149 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR153 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 153 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR153 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CXCL11 Biologics Sequence Review Report 2026: C-X-C motif chemokine 11 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CXCL11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CDHR3 Biologics Sequence Review Report 2026: Cadherin-related family member 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDHR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.